ImmunityBio submits response to FDA OPDP Warning Letter; outlines corrective actions

ImmunityBio, Inc.

Submitted comprehensive response to FDA OPDP Warning Letter dated March 13, 2026.
Identified podcast removed from corporate website; requested removal from third-party platforms.
TV advertisement cited in FDA letter was never broadcast or disseminated to the public.
Implementing enhanced compliance: executive training, expanded PRC protocols, external regulatory counsel.
CEO Richard Adcock reaffirms commitment to accurate and compliant promotional communications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.